Aadi Bioscience (AADI) – Press Releases
-
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting
-
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)
-
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update
-
Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update
-
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
-
Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa
-
Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference
-
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium
-
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium
-
Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations
-
Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update
-
Aadi Bioscience to Participate in Jefferies London Healthcare Conference
-
Aadi Bioscience to Report Third Quarter 2023 Results and Operational Update
-
Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting
-
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-
Aadi Bioscience Announces Poster Presentations at the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium
-
Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
-
Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer
-
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-
Aadi Bioscience to Participate at Upcoming Investor Conferences
-
Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update
-
Aadi Bioscience to Report Second Quarter 2023 Results and Operational Update
-
Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Aadi Bioscience to Participate in Upcoming Investor Events
-
Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial
-
Aadi Bioscience Announces Multiple Presentations on nab-Sirolimus at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting
-
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2023
-
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update
-
Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors
-
Aadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology (SGO) Annual Meeting on Women's Cancer
-
Aadi Bioscience to Report Fourth Quarter and Full-Year 2022 Results and Corporate Update
-
Aadi Bioscience Announces Leadership Transition
-
Aadi Bioscience to Present at the 43rd Annual Cowen Healthcare Conference
-
Aadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting
-
Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update
-
Aadi Bioscience Announces Planned Leadership Transition
-
Aadi Bioscience to Present at Upcoming Investor Conferences
-
Aadi Bioscience to Report Third Quarter 2022 Results and Corporate Update
-
Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium
-
Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium
-
Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C
-
Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing
-
Aadi Bioscience Announces Participation in Upcoming September Investor Conferences
-
Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update
-
Aadi Bioscience to Report Second Quarter 2022 Results and Corporate Update
-
Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes
-
Aadi Bioscience to Present at the Jefferies Global Healthcare Conference
-
Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications
-
Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting
Back to AADI Stock Lookup
